Measurement of myocardial infarct size in preclinical studies

Ischemic heart disease is a major cause of morbidity and mortality worldwide. Myocardial ischemia followed by reperfusion results in tissue injury termed ischemia/reperfusion injury which is characterized by decreased myocardial contractile function, occurrence of arrhythmias, and development of tis...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacological and toxicological methods 2010-03, Vol.61 (2), p.163-170
Main Authors: Csonka, Csaba, Kupai, Krisztina, Kocsis, Gabriella F., Novák, Gábor, Fekete, Veronika, Bencsik, Péter, Csont, Tamás, Ferdinandy, Péter
Format: Article
Language:English
Subjects:
Animals
Arrhythmia
Biomarkers
Cardiotonic Agents - pharmacology
Coloring Agents
Coronary Vessels - pathology
Drug Evaluation, Preclinical
Electrocardiography
Experimental
Heart
Infarct size
Infarction
Ischemia
Magnetic Resonance Imaging
Methods
Myocardial
Myocardial Infarction - mortality
Myocardial Infarction - pathology
Myocardial Reperfusion Injury - pathology
Myocardium - pathology
Positron-Emission Tomography
Reperfusion
Tetrazolium Salts
Tomography, Emission-Computed, Single-Photon
Tomography, X-Ray Computed
TTC
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ischemic heart disease is a major cause of morbidity and mortality worldwide. Myocardial ischemia followed by reperfusion results in tissue injury termed ischemia/reperfusion injury which is characterized by decreased myocardial contractile function, occurrence of arrhythmias, and development of tissue necrosis (infarction). These pathologies are all relevant as clinical consequences of myocardial ischemia/reperfusion injury and they are also important as experimental correlates and endpoints. The most critical determinant of acute and long-term mortality after myocardial infarction is the volume of the infarcted tissue. Therefore, development of cardioprotective therapies aims at reducing the size of the infarct developing due to myocardial ischemia/reperfusion injury. Different techniques are available to measure myocardial infarct size in humans and in experimental settings, however, accurate determination of the extent of infarction is necessary to evaluate interventions that may delay the onset of necrosis and/or limit the total extent of infarct size during ischemia/reperfusion. This paper highlights recent advances of the different techniques to measure infarct size.
ISSN:1056-8719
1873-488X
DOI:10.1016/j.vascn.2010.02.014